Abstract:Microglia and perivascular macrophages, myeloid-origin resident immune cells in the human brain, play crucial roles in Alzheimer’s disease (AD)[1][1]–[4][2]. However, the field lacks a unified taxonomy describing their heterogeneity and plasticity[5][3]. To address this, we applied single-cell profiling to two independent, demographically diverse cohorts. The first comprises 543,012 viable myeloid cells from 137 unique postmortem brain specimens, while the second consists of 289,493 myeloid nuclei from 1,470 donors. Collectively, they cover the human lifespan and varying degrees of AD neuropathology. We identify 13 transcriptionally distinct myeloid subtypes, including the “GPNMB” subtype that proliferates with AD. We distinguish two contrasting homeostatic microglial states in AD and with aging: the first (“FRMD4A”) wanes over time, while the second (“PICALM”) becomes more prevalent. By prioritizing AD-risk genes, including PTPRG, DPYD, and IL15, and placing them into a regulatory hierarchy, we identify common upstream transcriptional regulators, namely MITF and KLF12, that regulate the expression of AD-risk genes in the opposite directions. Through the construction of cell-to-cell interaction networks, we identify candidate ligand-receptor pairs, including APOE:SORL1 and APOE:TREM2, associated with AD progression. We show polygenic risk for AD predisposes and prioritize the GPNMB subtype as a therapeutic target of early intervention. Our findings delineate the relationship between distinct functional states of myeloid cells and their pathophysiological response to aging and AD, providing a significant step toward the mechanistic understanding of the roles of microglia in AD and the identification of novel therapeutics. ### Competing Interest Statement F.J.T. consults for Immunai Inc., Singularity Bio B.V., CytoReason Ltd, Omniscope Ltd, Cellarity, and has ownership interest in Dermagnostix GmbH and Cellarity. The remaining authors declare no competing interests. ### Funding Statement We acknowledge the National Institute on Aging for their generous support in funding this research with the following NIH grants: R01AG065582 (PR, VH), R01AG067025 (PR, VH), and R01AG082185 (PR, VH, DL). ROSMAP is supported by P30AG10161, P30AG72975, R01AG15819, R01AG17917. U01AG46152, U01AG61356.Human Brain Collection Core (HBCC) at the National Institute of Mental Health-Intramural Research Program is supported by the NIMH-IRP under project ZIC MH002903. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of Mount Sinai gave ethical approval for this work. Ethics committee/IRB of James J. Peters Department of Veterans Affairs Medical Center gave ethical approval for this work. Ethics committee/IRB of Rush Alzheimer's Disease Center gave ethical approval for this work. Ethics committee/IRB of National Institute of Mental Health Human Brain Collection Core gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes [1]: #ref-1 [2]: #ref-4 [3]: #ref-5

Contributions of genetic variation in astrocytes to cell and molecular mechanisms of risk and resilience to late onset Alzheimer's disease

[P3–170]: HUMAN IPSC‐DERIVED ALZHEIMER's DISEASE ASTROCYTES RECAPITULATE DISEASE‐RELATED PHENOTYPES

Stem cell-derived neurons reflect features of protein networks, neuropathology, and cognitive outcome of their aged human donors

PSEN1 Mutant Ipsc-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer's Disease

EXPLORING CELL AUTONOMOUS AND NON-CELL AUTONOMOUS EFFECTS OF APOE GENOTYPE IN IPSC-DERIVED ASTROCYTES AND NEURONS

Plasticity of Human Microglia and Brain Perivascular Macrophages in Aging and Alzheimer’s Disease

Identifying the molecular systems that influence cognitive resilience to Alzheimer's disease in genetically diverse mice

Gene expression and chromatin accessibility comparison in iPSC-derived microglia in African, European, and Amerindian genomes in Alzheimer's patients and controls.

Human Ipsc-Derived Neurons and Astrocytes As Models of Neurodegeneration, Neuroinflammation and Vesicular Trafficking in Alzheimer's Disease

APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer’s Disease Phenotypes in Human iPSC-Derived Brain Cell Types

Functional characterization of a single nucleotide polymorphism associated with Alzheimer's disease in a hiPSC-based neuron model

Alterations in protein kinase networks in astrocytes and neurons derived from patients with familial Alzheimer’s Disease

Genetic variants and functional pathways associated with resilience to Alzheimer’s disease

Limitations of the human iPSC-derived neuron model for early-onset Alzheimer's disease

Genetic and multi-omic risk assessment of Alzheimer's disease implicates core associated biological domains

iPSC-derived PSEN2 (N141I) astrocytes and microglia exhibit a primed inflammatory phenotype

Genetic, Clinical Underpinnings of Brain Change along Two Neuroanatomical Dimensions of Clinically-defined Alzheimer’s Disease

Molecular basis of astrocyte diversity and morphology across the CNS in health and disease

Genetics impact risk of Alzheimer’s disease through mechanisms modulating structural brain morphology in late life

Cross-disorder and disease-specific pathways in dementia revealed by single-cell genomics

Systematic review of human post-mortem immunohistochemical studies and bioinformatics analyses unveil the complexity of astrocyte reaction in Alzheimer's disease